Article

Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology

2020-03-09

Abstract excerpt

T cells engineered to recognize and kill tumor cells have emerged as powerful agents for combating cancer. Nonetheless, our ability to engineer T cells remains relatively primitive. Aside from CAR T cells for treating B cell malignancies, most T cell therapies are risky, toxic, and often ineffective, especially those that target solid cancers. To fulfill the promise of cell-based therapies, we must transform cell...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7b0c3d57-1c40-5f5c-b2aa-b13316dbe5c9
DOI: 10.1146/annurev-cancerbio-030419-033657

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic BiologyDOI 10.1146/annurev-cancerbio-030419-033657Read

Emerging Cellular Therapies for CancerSemantic proximity Read

T cell engineering as therapy for cancer and HIV: our synthetic futureSemantic proximity Read

CAR T Cell Therapy: A Versatile Living DrugSemantic proximity Read

Strategies to genetically engineer T cells for cancer immunotherapySemantic proximity Read

Cancer T-cell therapy: building the foundation for a cureSemantic proximity Read

Engineered T cells for cancer therapySemantic proximity Read

Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic ImpactSemantic proximity Read

Engineered T cells for anti-cancer therapySemantic proximity Read

Four challenges to CAR T cells breaking the glass ceilingSemantic proximity Read

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptorSemantic proximity Read

Therapeutic T cell engineeringSemantic proximity Read

Synthetic Hybrid Receptors for Safer and Programmable T Cell TherapySemantic proximity Read